A Retrospective Study of the C-Reactive Protein to Lymphocyte Ratio and Disease Severity in 108 Patients with Early COVID-19 Pneumonia from January to March 2020 in Wuhan, China

Yang, Miao; Chen, Xiaoping; Xu, Yancheng

doi:10.12659/msm.926393

Cited by 38 publications

(59 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A surprisingly high number of papers have focused on circulating CRP levels in COVID-19 patients, with multiple lines of evidence showing the prognostic value of this biomarker [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]. Studies addressing the clinical usefulness of CRP have mostly reported a positive association between disease severity and baseline values.…”

Section: Crp Levelmentioning

confidence: 99%

“…Despite the retrospective single-center design of this study, variables with missing values were not included in the analysis, which strengthens the findings. Yang, et al [19] analyzed CRP levels in 108 COVID-19 patients to assess its effectiveness as a biomarker of disease severity. The CRP level and CRP-to-LC ratio had high prognostic value in the early disease stage.…”

Section: Crp Levelmentioning

confidence: 99%

“…Although coronavirus disease 2019 (COVID- 19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is well known worldwide, it is impossible to predict how the disease will manifest in an individual. The manifestations of symptomatic COVID-19 vary widely from mild fever ( > 37.5°C) and cough to acute respiratory distress syndrome (ARDS) and death, and the disease follows an unpredictable course.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Biomarkers for Prognosis and Treatment Response in COVID-19 Patients

2021

View full text Add to dashboard Cite

During a severe infection such as coronavirus disease 2019 , the level of almost all analytes can change, presenting a correlation with disease severity and survival; however, a biomarker cannot be translated into clinical practice for treatment guidance until it is proven to have a significant impact. Several studies have documented the association between COVID-19 severity and circulating levels of C-reactive protein (CRP) and interleukin-6, and the accuracy of the CRP level in predicting treatment responses has been evaluated. Moreover, promising findings on prothrombin and D-dimer have been reported. However, the clinical usefulness of these biomarkers in COVID-19 is far from proven. The burst of data generation during this pandemic has led to the publication of numerous studies with several notable drawbacks, weakening the strength of their findings. We provide an overview of the key findings of studies on biomarkers for the prognosis and treatment response in COVID-19 patients. We also highlight the main drawbacks of these studies that have limited the clinical use of these biomarkers.

show abstract

Section: Crp Levelmentioning

confidence: 99%

Section: Crp Levelmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers for Prognosis and Treatment Response in COVID-19 Patients

2021

View full text Add to dashboard Cite

show abstract

“…Similarly, lymphopenia can be a good indicator of disease severity [ 13 ]. It was also suggested that CRP to lymphocyte ratio can be a better marker than lymphocyte count alone for assessment of the disease severity in the early stage of disease [ 14 ]. In addition, 10.6% of patients in our study presented with elevated serum amylase and lipase.…”

Section: Discussionmentioning

confidence: 99%

Chest CT performance and features of COVID-19 in the region of Abu Dhabi, UAE: a single institute study

et al. 2021

View full text Add to dashboard Cite

Objective We aim to investigate high-resolution CT features of COVID-19 infection in Abu Dhabi, UAE, and to compare the diagnostic performance of CT scan with RT-PCR test. Methods Data of consecutive patients who were suspected to have COVID-19 infection and presented to our hospital were collected from March 2, 2020, until April 12, 2020. All patients underwent RT-PCR test; out of which 53.8% had chest CT scan done. Using RT-PCR as a standard reference, the sensitivity and specificity of the CT scan were calculated. We also analyzed the most common imaging findings in patients with positive RT-PCR results. Results The typical HRCT findings were seen in 50 scans (65.8%) out of total positive ones; 44 (77.2%) with positive RT-PCR results and 6 (31.6%) with negative results. The peripheral disease distribution was seen in 86%, multilobe involvement in 70%, bilateral in 82%, and posterior in 82% of the 50 scans. The ground glass opacities were seen in 50/74 (89.3%) of the positive RT-PCR group. The recognized GGO patterns in these scans were: rounded 50%, linear 38%, and crazy-paving 24%. Using RT-PCR as a standard of reference, chest HRCT scan revealed a sensitivity of 68.8% and specificity of 70%. Conclusion The commonest HRCT findings in patients with COVID-19 pneumonia were peripheral, posterior, bilateral, multilobe rounded ground-glass opacities. The performance of HRCT scan can vary depending on multiple factors.

show abstract

“…Glucocorticoids are even suggested for SARS and COVID-19 treatment to reduce inflammation (Cinatl Jr et al 2005 ; Xiang et al 2020 ). However, since high doses are recommended for acute respiratory infections, prolonged use may lead to opportunistic infections in the background of immune suppression (Klein et al 2001 ; Cinatl Jr et al 2005 ; Lossignol 2016 ; Yang et al 2020a ). Since cancer patients are in the high-risk group for COVID-19, addressing SARS-CoV-2 induced inflammation alone with high doses of glucocorticoids can lower host immunity and thus, can aggravate both cancer and virus spread and can invite other infections to occur in cancer patients (Slimano et al 2020 ; Hanna et al 2020 ; Russell et al 2020 ; Table 4 ).…”

Section: Potential Inhibitors Of Cytokine Storm In the Context Of Sarmentioning

confidence: 99%

Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting

Subbarao

2021

Inflammopharmacol

View full text Add to dashboard Cite

Inflammation is an intrinsic defence mechanism triggered by the immune system against infection or injury. Chronic inflammation allows the host to recover or adapt through cellular and humoral responses, whereas acute inflammation leads to cytokine storms resulting in tissue damage. In this review, we present the overlapping outcomes of cancer inflammation with virus-induced inflammation. The study emphasises how anti-inflammatory drugs that work against cancer inflammation may work against the inflammation caused by the viral infection. It is established that the cytokine storm induced in response to SARS-CoV-2 infection contributes to disease-associated mortality. While cancer remains the second among the diseases associated with mortality worldwide, cancer patients' mortality rates are often observed upon extended periods after illness, usually ranging from months to years. However, the mortality rates associated with COVID-19 disease are robust. The cytokine storm induced by SARS-CoV-2 infection appeared to be responsible for the multi-organ failure and increased mortality rates. Since both cancer and COVID-19 disease share overlapping inflammatory mechanisms, repurposing some anticancer and anti-inflammatory drugs for COVID-19 may lower mortality rates. Here, we review some of these inflammatory mechanisms and propose some potential chemotherapeutic agents to intervene in them. We also discuss the repercussions of anti-inflammatory drugs such as glucocorticoids and hydroxychloroquine with zinc or antiviral drugs such as ivermectin and remdesivir against SARS-CoV-2 induced cytokine storm. In this review, we emphasise on various possibilities to reduce SARS-CoV-2 induced cytokine storm.

show abstract

A Retrospective Study of the C-Reactive Protein to Lymphocyte Ratio and Disease Severity in 108 Patients with Early COVID-19 Pneumonia from January to March 2020 in Wuhan, China

Cited by 38 publications

References 30 publications

Biomarkers for Prognosis and Treatment Response in COVID-19 Patients

Biomarkers for Prognosis and Treatment Response in COVID-19 Patients

Chest CT performance and features of COVID-19 in the region of Abu Dhabi, UAE: a single institute study

Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting

Contact Info

Product

Resources

About